Back to search
Resectable Intrahepatic Cholangiocarcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Resectable Intrahepatic Cholangiocarcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Resectable Intrahepatic Cholangiocarcinoma trials you may qualify forThis phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high…
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer th…
To find out if adding pembrolizumab to standard of care chemotherapy drugs (cisplatin and gemcitabine) will improve long-term response of intrahepatic cholangio…
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microsco…
Treatment of intrahepatic cholangiocarcinoma (ICC) remains difficult. Many patients have unresectable tumors, and survival after resection was only slightly imp…
Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcin…
Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absen…
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect…
Among resectable biliary tract cancers (BTC) patients, surgery has historically been the standard treatment, but even with curative surgery, the cure rates rema…